A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients

BMC Urology

Research Article

Masashi Nomura¹  Kazuhiro Suzuki¹  Kazuto Ito¹  Yoshitaka Sekine¹  Takahiro Syuto¹  Hidekazu Koike¹  Yasuhiro Shibata¹  Yoshiyuki Miyazawa¹  Hiroshi Matsui¹ 

[1] Department of Urology, Gunma University Graduate School of Medicine, 3-9-22 Showa-machi, 371-8511, Maebashi, Gunma, Japan;

关键词: Prostate cancer;    GnRH antagonist;    Adrenal androgen;   

DOI  :  10.1186/s12894-017-0261-z

 received in 2016-08-03, accepted in 2017-08-23,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundAdrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in patients treated with a GnRH antagonist.MethodsThis study included 47 patients with histologically proven prostate cancer. All of the patients were treated with the GnRH antagonist degarelix. The mean patient age was 73.6 years. Pre-treatment blood samples were collected from all of the patients, and post-treatment samples were taken at 1, 3, 6, and 12 months after starting treatment. Testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), 17β-estradiol (E2), and androstenedione (A-dione) were measured by liquid chromatography-mass spectrometry. Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone, and follicle-stimulating hormone levels were measured by electro-chemiluminescence immunoassays.ResultsA significant reduction in T level (97.3% reduction) was observed in the patients 1 month after initiating treatment. In addition, levels of DHT, E2, DHEA-S, and A-dione decreased 1 month after initiating treatment (93.3, 84.9, 16.8, and 35.9% reduction, respectively). T, DHT, E2, DHEA-S, and A-dione levels remained significantly suppressed (97.1, 94.6, 85.3, 23.9, and 40.5% reduction, respectively) 12 months after initiating treatment. A significant decrease in DHEA level (15.4% reduction) was observed 12 months after initiating treatment.ConclusionsSerum adrenal androgen levels decreased significantly in patients treated with a GnRH antagonist. Thus, long-term GnRH antagonist treatment may reduce serum adrenal androgen levels.

【 授权许可】

CC BY   
© The Author(s). 2017